FTY720 + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Progressive Multiple Sclerosis
Conditions
Primary Progressive Multiple Sclerosis
Trial Timeline
Jul 28, 2008 → Jun 22, 2015
NCT ID
NCT00731692About FTY720 + Placebo
FTY720 + Placebo is a phase 3 stage product being developed by Novartis for Primary Progressive Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00731692. Target conditions include Primary Progressive Multiple Sclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00785083 | Phase 2 | Completed |
| NCT00731692 | Phase 3 | Terminated |
| NCT00537082 | Phase 2 | Completed |
| NCT00333138 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Progressive Multiple Sclerosis